New Gadolinium-based Contrast Agent Elucirem Will Soon Be Available for MRIs

If you have multiple sclerosis (MS), you’ve probably had several MRIs “with” and “without.” The “with” means injecting a contrast agent containing gadolinium into a vein. The agent then travels into the brain, where it “lights up” areas of active inflammation that otherwise would be difficult or impossible for doctors to see.

Using a gadolinium-based contrast agent is an important part of the diagnostic and disease-tracking process for people with MS. But there have been concerns about the possibility that some gadolinium may remain in the patient’s body long after the MRI.

Recommended Reading

September 19, 2022 News by Marisa Wexler, MS

Gut Bacteria Are Altered in MS, Linked to Disease Progression

Concerns about gadolinium

Gadolinium is a silvery-white earth metal. When used as a contrast agent, it’s mixed with other chemical elements that surround it to prevent it from harming the body.

Although 90% of the gadolinium is supposed to quickly exit the body via the urinary system in patients with normal kidneys, in 2017, the U.S. Food and Drug Administration (FDA) issued a safety statement noting that some people who have been injected with it several times may have retained gadolinium deposits. Such was the case for former MS News Today columnist Debi Wilson, whose naturopathic doctor discovered a small amount in her body a few years ago.

According to the FDA, there’s no indication that such deposits are dangerous, but some patients believe they are. Because of this concern, the FDA advises medical providers not to use gadolinium-based contrast agents unnecessarily. The Consortium of Multiple Sclerosis Centers considers MRIs with gadolinium to be essential for patients with active disease or whose disease course is rapidly or unexpectedly declining. But it recommends that they be used judiciously on other MS patients and suggests that they may not be needed for routine MS monitoring.

Enter Elucirem

In late September, the FDA approved a gadolinium-based contrast agent called Elucirem (gadopiclenol). Elucirem has a high relaxivity, a measurement of the sensitivity of a contrast agent. The medical imaging company Guerbet said in a press release that high relaxivity allows a radiologist to obtain the same result as with conventional contrast agents, but with only half the amount of gadolinium. A spokesperson for Guerbet told me in an email that the company expects Elucirem to be available in the U.S. in the first quarter of 2023.

Will Elucirem be used for MRIs in MS?

I wondered what radiologists in the U.S. thought about this new contrast agent, so I reached out, again by email, to the American College of Radiology (ACR), which represents more than 41,000 radiologists. I asked if the organization expects its members to begin using Elucirem for routine MRIs of MS patients once it becomes available. I also asked if there are particular situations in which it would or wouldn’t be appropriate, and if Elucirem would need to be requested as the contrast agent by the physician ordering the scan.

The answer from public affairs manager Kevin R. Walter was, “The ACR as a policy does not typically monitor or take positions on individual products or companies, thus cannot speculate on radiologists’ use of Elucirem.”

It seems to be up to us, then, to ask our neurologists about Elucirem after it becomes available next year. It certainly seems worth raising the question before your next MRI.

You’re invited to visit my personal blog at www.themswire.com.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis.